Azapiron (Serbo-Croatian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Azapiron" in Serbo-Croatian language version.

refsWebsite

Global rank Serbo-Croatian rank

9nih.gov

4^th place

3^rd place

5doi.org

2^nd place

1archive.org

6^th place

5^th place

1elsevier.com

610^th place

525^th place

1wkhealth.com

low place

2,251^st place

1wiley.com

222^nd place

57^th place

archive.org (Global: 6^th place; Serbo-Croatian: 5^th place)

Cadieux RJ (May 1996). „Azapirones: an alternative to benzodiazepines for anxiety”. American Family Physician 53 (7): 2349–53. PMID 8638511.

doi.org (Global: 2^nd place; Serbo-Croatian: 2^nd place)

dx.doi.org

Chessick CA, Allen MH, Thase M, et al. (2006). Chessick, Cheryl A. ur. „Azapirones for generalized anxiety disorder”. Cochrane Database of Systematic Reviews (Online) 3: CD006115. DOI:10.1002/14651858.CD006115. PMID 16856115.
Van Ameringen M, Mancini C, Wilson C (July 1996). „Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia”. Journal of Affective Disorders 39 (2): 115–21. DOI:10.1016/0165-0327(96)00030-4. PMID 8827420.
Dimitriou EC, Dimitriou CE (December 1998). „Buspirone augmentation of antidepressant therapy”. Journal of Clinical Psychopharmacology 18 (6): 465–9. DOI:10.1097/00004714-199812000-00009. PMID 9864079.
Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH (June 2001). „Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study”. The Journal of Clinical Psychiatry 62 (6): 448–52. DOI:10.4088/JCP.v62n0608. PMID 11465522.
Yamada K, Yagi G, Kanba S (April 2003). „Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial”. Psychiatry and Clinical Neurosciences 57 (2): 183–7. DOI:10.1046/j.1440-1819.2003.01099.x. PMID 12667165. ^{[mrtav link]}

elsevier.com (Global: 610^th place; Serbo-Croatian: 525^th place)

linkinghub.elsevier.com

Van Ameringen M, Mancini C, Wilson C (July 1996). „Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia”. Journal of Affective Disorders 39 (2): 115–21. DOI:10.1016/0165-0327(96)00030-4. PMID 8827420.

nih.gov (Global: 4^th place; Serbo-Croatian: 3^rd place)

ncbi.nlm.nih.gov

Eison AS (June 1990). „Azapirones: history of development”. Journal of Clinical Psychopharmacology 10 (3 Suppl): 2S–5S. PMID 1973936.
Cadieux RJ (May 1996). „Azapirones: an alternative to benzodiazepines for anxiety”. American Family Physician 53 (7): 2349–53. PMID 8638511.
Chessick CA, Allen MH, Thase M, et al. (2006). Chessick, Cheryl A. ur. „Azapirones for generalized anxiety disorder”. Cochrane Database of Systematic Reviews (Online) 3: CD006115. DOI:10.1002/14651858.CD006115. PMID 16856115.
Feighner JP, Boyer WF (1989). „Serotonin-1A anxiolytics: an overview”. Psychopathology 22 Suppl 1: 21–6. PMID 2567039.
Van Ameringen M, Mancini C, Wilson C (July 1996). „Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia”. Journal of Affective Disorders 39 (2): 115–21. DOI:10.1016/0165-0327(96)00030-4. PMID 8827420.
Bouwer C, Stein DJ (April 1997). „Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression”. South African Medical Journal 87 (4 Suppl): 534–7, 540. PMID 9180827.
Dimitriou EC, Dimitriou CE (December 1998). „Buspirone augmentation of antidepressant therapy”. Journal of Clinical Psychopharmacology 18 (6): 465–9. DOI:10.1097/00004714-199812000-00009. PMID 9864079.
Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH (June 2001). „Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study”. The Journal of Clinical Psychiatry 62 (6): 448–52. DOI:10.4088/JCP.v62n0608. PMID 11465522.
Yamada K, Yagi G, Kanba S (April 2003). „Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial”. Psychiatry and Clinical Neurosciences 57 (2): 183–7. DOI:10.1046/j.1440-1819.2003.01099.x. PMID 12667165. ^{[mrtav link]}

wiley.com (Global: 222^nd place; Serbo-Croatian: 57^th place)

www3.interscience.wiley.com

Yamada K, Yagi G, Kanba S (April 2003). „Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial”. Psychiatry and Clinical Neurosciences 57 (2): 183–7. DOI:10.1046/j.1440-1819.2003.01099.x. PMID 12667165. ^{[mrtav link]}

wkhealth.com (Global: low place; Serbo-Croatian: 2,251^st place)

meta.wkhealth.com

Dimitriou EC, Dimitriou CE (December 1998). „Buspirone augmentation of antidepressant therapy”. Journal of Clinical Psychopharmacology 18 (6): 465–9. DOI:10.1097/00004714-199812000-00009. PMID 9864079.

Azapiron (Serbo-Croatian Wikipedia)

archive.org (Global: 6th place; Serbo-Croatian: 5th place)

doi.org (Global: 2nd place; Serbo-Croatian: 2nd place)